Eli Lilly Says Once-Weekly Insulin Meets Key Goal in Two Studies
By Colin Kellaher
Eli Lilly on Thursday said a pair of late-stage studies of its proposed once-weekly insulin efsitora alfa met their primary endpoints.
The Indianapolis drugmaker said efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally in the Phase 3 studies in adults with type 2 diabetes using insulin for the first time and those who require multiple daily injections.
Eli Lilly said efsitora was safe and well-tolerated in both studies, adding that it expects topline readouts from three additional trials later this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 16, 2024 07:34 ET (11:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Broadcom Stock a Buy, a Sell, or Fairly Valued?
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
With a 4% Dividend Yield and Significant Growth Potential, This Stock Is a Buy
-
10 Stocks the Best Fund Managers Have Been Buying
-
GE Aerospace Stock Has Skyrocketed 86%. Is It a Buy?
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?